Table 2 Patient-reported outcome measures between baseline and Week 2.

From: A mixed-methods pilot study of handheld fan for breathlessness in interstitial lung disease

 

Fan groupa

Control groupa

Treatment effectb

p value

Baseline

Week 2

Baseline

Week 2

Dyspnoea-12

16.1 ± 2.2

13.4 ± 2.3

13.3 ± 2.2

12.8 ± 2.2

− 2.2 (− 6.4, 1.9)

0.29

K-BILD Breathlessness & Activities

29.2 ± 3.9

32.2 ± 3.9

32.5 ± 3.7

37.0 ± 3.7

− 1.5 (− 8.9, 5.9)

0.69

K-BILD Chest Symptoms

47.0 ± 5.2

56.1 ± 5.4

59.6 ± 5.0

58.8 ± 5.2

10 (− 5.1, 25.1)

0.19

K-BILD Psychological Symptoms

51.7 ± 4.2

53.4 ± 4.2

56.9 ± 4.1

57.5 ± 4.1

1.1 (− 4.1, 6.3)

0.40

K-BILD Total

48.0 ± 2.5

50.3 ± 2.5

52.3 ± 2.4

54.0 ± 2.4

0.7 (− 3.3, 4.7)

0.33

Self-efficacyc

5.4 ± 0.6

5.7 ± 0.7

5.5 ± 0.6

5.7 ± 0.6

0.07 (− 1.9, 2.0)

0.94

Activities of daily livingd

14.4 ± 0.9

14.6 ± 1.0

15.1 ± 0.9

16.9 ± 0.9

− 2.5 (− 4.8, 0.3)

0.08

Life-spacee

58.6 ± 6.3

58.0 ± 6.4

66.6 ± 6.1

63.7 ± 6.1

2.4 (− 10.4, 15.2)

0.72

  1. Measured using: cSelf-efficacy for Managing Chronic Disease 6-item Scale; dManchester Respiratory Activities of Daily Living Questionnaire; eUniversity of Alabama at Birmingham Study of Aging Life-Space Assessment.
  2. Data are expressed as amean ± standard error or bmean difference (95% confidence interval). P values are between group comparison for mean difference.
  3. K-BILD King’s Brief Interstitial Lung Disease.
Back to article page